U.S. Water Utilities Stock News

Charles Schwab FY 2025 Earnings Snapshot Charles Schwab (SCHW) closed FY 2025 with fourth quarter revenue of US$6.3 billion and basic EPS of US$1.34, alongside net income excluding extra items of US$2.4 billion, putting a solid set of headline numbers in front of investors. The company has seen quarterly revenue move from US$5.3 billion and EPS of US$0.94 in Q4 2024 to US$6.3 billion and EPS of US$1.34 in Q4 2025, alongside trailing twelve month EPS of US$4.67 and revenue of US$24.0 billion...

Earlier in January 2026, AtriCure issued 2026 revenue guidance of approximately US$600 million to US$610 million and amended its asset-based revolving credit facility, extending the term, lowering interest rates and maintaining up to US$125 million in borrowing capacity with the option to increase to US$165 million. Together, the higher revenue outlook and more flexible, lower-cost credit line highlight management’s confidence in AtriCure’s growth plans and liquidity position. Next, we’ll...

United Airlines FY 2025 Earnings Snapshot United Airlines Holdings (UAL) has wrapped up FY 2025 with Q4 revenue of US$15.4b and basic EPS of US$3.19, supported by net income of US$1,044m. Over recent quarters, the company has seen revenue move from US$14.7b in Q4 2024 to US$15.2b in Q3 2025 and US$15.4b in Q4 2025. Basic EPS over the same Q4 periods shifted from US$2.94 to US$3.19, setting up a results season where investors can weigh steady top line and earnings against how efficiently those...

Why Day One Biopharmaceuticals is in the spotlight Day One Biopharmaceuticals (DAWN) is back on investors’ radar after releasing preliminary 2025 OJEMDA revenue figures and issuing fresh 2026 guidance that ties directly to prescription and patient demand trends. The company reported unaudited OJEMDA net product revenue of approximately US$52.8 million for the fourth quarter of 2025 and US$155.4 million for the full year, with prescription volumes reaching 1,394 in the quarter. Management also...

In mid-January 2026, Sensata Technologies announced the launch of its STEV high-voltage contactor series, a scalable, customizable solution designed to improve safety, efficiency and integration across battery electric and plug-in hybrid vehicle platforms from passenger cars to heavy-duty trucks. A distinctive aspect of the STEV lineup is its combination of bidirectional current capability, hermetic ceramic sealing and global in-region manufacturing, positioning Sensata as a key enabler of...

Teledyne Technologies (TDY) has wrapped up FY 2025 with fourth quarter revenue of US$1.6b and basic EPS of US$5.60, alongside trailing twelve month revenue of US$6.1b and EPS of US$18.88 that frame the latest print in a broader earnings run. Over the past six quarters in the data, quarterly revenue has ranged from US$1.44b to US$1.61b, while basic EPS has moved between US$4.03 and US$5.61, giving investors a clear view of how the top and bottom lines have tracked together through recent...

Corsair Gaming recently used CES 2026 to showcase an expanded ecosystem that connects high-performance gaming hardware, Stream Deck workflows, and early support for Model Context Protocol to enable natural language and voice interactions with AI agents. An especially interesting highlight was the GALLEON 100 SD, a CES Innovation Award-winning keyboard that fuses mechanical gaming performance with integrated Stream Deck controls, signaling Corsair’s push to make AI-enabled, multi-function...

If you are wondering whether Universal Technical Institute's share price still offers value after recent moves, it helps to step back and look at what the current market price might be implying. The stock last closed at US$28.15, with returns of 5.9% over the past week, 5.0% over the last month, 13.3% year to date, 6.1% over 1 year, and very large gains over 3 and 5 years. Recent attention on Universal Technical Institute has focused on its role in career and technical education, as...

Riverwater Partners recently highlighted IRADIMED CORPORATION as the top contributor to its Micro Opportunities Strategy in 2025, following record Q3 2025 revenue of US$21.2 million and FDA approval of the company’s MRI-compatible 3870 IV infusion pump in July 2025. Beyond the financial headlines, IRADIMED’s combination of accelerating revenue, new FDA-cleared technology and a special dividend, alongside insider share sales and a “Moderate Buy” analyst consensus, paints a complex picture of...

If we want to find a potential multi-bagger, often there are underlying trends that can provide clues. Amongst other...

Why VK2735’s latest trial results matter for Viking Therapeutics (VKTX) Viking Therapeutics (VKTX) is back in focus after publishing Phase 2 VENTURE trial results for its dual GLP-1/GIP candidate VK2735 and confirming full enrollment in two large Phase 3 obesity and diabetes studies. See our latest analysis for Viking Therapeutics. VKTX’s share price has been choppy around the latest VK2735 updates, with a 7 day share price return of 4.71% but a 30 day share price return of 8.32% and a year...

If you are wondering whether Upbound Group's current share price reflects its underlying value, you are not alone. This article focuses squarely on what the numbers say about the stock. The share price closed at US$19.43, with a 9.7% gain over the last 30 days but a 29.4% decline over the past year. This raises questions about how the market is currently pricing the business and its risks. Recent news flow for Upbound Group has included ongoing commentary around the rent to own and lease to...

AbCellera Biologics (ABCL) has begun dosing patients in the Phase 2 portion of its Phase 1/2 trial for ABCL635, a potential first in class non hormonal treatment for menopausal vasomotor symptoms. See our latest analysis for AbCellera Biologics. The ABCL635 Phase 2 start comes as AbCellera’s 30 day share price return of 15.05% and year to date share price return of 24.78% contrast with a 3 year total shareholder return of 58.89% decline, suggesting sentiment has improved recently after a...

If you are wondering whether Newmark Group's share price still offers value after a long run on the market, this article breaks down what the current valuation implies for you as a shareholder or potential investor. Newmark Group's stock last closed at US$17.75, with returns of 5.7% over 7 days, 1.5% over 30 days, 4.6% year to date, 30.1% over 1 year and 113.0% over 3 years. These figures raise fair questions about how much of the story is already reflected in the price. Recent coverage has...

National Bank Financial recently upgraded RB Global (NYSE:RBA), highlighting market share gains and contract wins in Australia and the UK. The firm pointed to new agreements with Suncorp and Direct Line as key drivers of RB Global's expanding presence in vehicle and asset remarketing. The upgrade focuses on the company's growing international footprint and its potential to win additional business in core markets. RB Global runs auctions and related services that help businesses sell heavy...

Commerce Bancshares (NasdaqGS:CBSH) has closed its acquisition of FineMark National Bank & Trust. The deal expands Commerce's wealth management and private banking reach into Florida, Arizona, and South Carolina. FineMark will operate as a division within Commerce Bank while maintaining existing client relationships. For investors, this move adds more scale and breadth to Commerce Bancshares' long standing banking and wealth management franchise. Wealth management and private banking have...

Event context and recent stock performance Amicus Therapeutics (FOLD) has caught investor attention after a sharp share price move in the past 3 months, with the stock returning about 69% over that period. See our latest analysis for Amicus Therapeutics. That sharp 68.82% 90 day share price return sits alongside a 50.42% 1 year total shareholder return, while the 5 year total shareholder return of a 24.39% decline shows longer term holders have had a tougher journey, which suggests that...

Latest FY 2025 Earnings Snapshot Interactive Brokers Group (IBKR) closed out FY 2025 with Q4 total revenue of US$1.7b and basic EPS of US$0.64, alongside net income of US$284m, setting a clear reference point for the year just finished. The company has seen quarterly revenue move from US$1.4b in Q1 2025 to US$1.7b in Q4 2025, while basic EPS has ranged from US$0.49 in Q1 to US$0.64 in Q4, providing a clear view of how the top and bottom line have tracked through the year as you weigh the...

If you are wondering whether Ormat Technologies at around US$122 is priced attractively or asking too much, you are not alone. The stock shows returns of 1.9% over 7 days, 8.8% over 30 days, 7.3% year to date, 90.4% over 1 year, 35.1% over 3 years and 10.4% over 5 years. This naturally raises questions about how this performance lines up with the current share price. Recent news coverage has focused on Ormat Technologies as a US listed utilities business with exposure to renewable energy...

Solstice Advanced Materials, Inc. ( NASDAQ:SOLS ) shares have continued their recent momentum with a 27% gain in the...

Lianhe Sowell International Group Ltd ( NASDAQ:LHSW ) shareholders are no doubt pleased to see that the share price has...

Karman Holdings Inc. ( NYSE:KRMN ) shareholders have had their patience rewarded with a 33% share price jump in the...

FTAI Infrastructure Inc. ( NASDAQ:FIP ) shareholders would be excited to see that the share price has had a great...

As of January 2026, the U.S. stock market has experienced a notable rebound, with major indices such as the Nasdaq, Dow Jones Industrial Average, and S&P 500 each rising about 1.2% following geopolitical developments that eased investor concerns. In this dynamic environment, high-growth tech stocks in the United States continue to capture attention due to their potential for innovation and resilience amidst fluctuating market conditions; identifying promising stocks often involves assessing...